Mutations in the PTEN/MMAC1 gene have been identi®ed in several types of human cancers and cancer cell lines, including brain, endometrial, prostate, breast, thyroid, and melanoma. In this study, we screened a total of 96 hepatocellular carcinoma (HCC) samples from Taiwan, where HCC is the leading cancer in males and third leading cancer in females, for mutations in the PTEN/MMAC1 gene. Complete sequence analysis of these samples demonstrated a missense mutation in exon 5 (K144I) and exon 7 (V255A) from HCC samples B6-21 and B6-2, respectively. A putative splice site mutation was also detected in intron 3 from sample B6-2. Both B6-21 and B6-2 were previously shown to contain missense mutations in the coding sequences of the p53 gene. Functional studies with the two missense mutations demonstrated that while mutation V255A in exon 7 resulted in a loss of phosphatase activity, mutation K144I in exon 5 retained its phosphatase activity. Additionally, we identi®ed a silent mutation (P96P) in exon 5 of the PTEN/MMAC1 gene from HCC sample B6-22. These data provide the ®rst evidence that the PTEN/MMAC1 gene is mutated in a subset of HCC samples.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world (Montesano et al., 1997) . The incidence of HCC varies in its geographic distribution. It has the highest incidence in Qidong, China and sub-Saharan, Africa , however, it is relatively rare in North America and Europe. The increased incidence of HCC in China and Africa is mainly caused by the high level of dietary a¯atoxin B 1 (AFB 1 ) exposure, and the high incidence of chronic hepatitis B virus (HBV) infection (Peers et al., 1976; Yeh et al., 1989) . Genetic analysis of 26 HCC samples from these two areas revealed a high incidence of an AGG?AGT transversional changes in codon 249 of the p53 gene (Hsu et al., 1991; Bressac et al., 1991) . By contrast, p53 mutations in HCC samples from low AFB 1 exposure areas occurred less frequently and were not con®ned to cordon 249 (Buetow et al., 1992; Aguilar et al., 1994) .
In addition to p53, other tumor suppressor genes have also been implicated in HCC. A loss of heterozygosity (LOH) of the retinoblastoma (RB) and APC genes was also detected in HCC samples from China (44 and 7% respectively) (Fujimoto et al., 1994) . Recently, a series of somatic mutations in the coding sequence of the b-catenin gene was identi®ed in 18% (14/75) of HCC samples screened (Miyoshi et al., 1998) . Activation of proto-oncogenes, such as c-myc and cyclin D1, by DNA ampli®cation has also been observed in a subset of HCC samples (Peng et al., 1993; Zhang et al., 1993; Nishida et al., 1994) .
PTEN/MMAC1/TEP1, a tumor suppressor gene, was ®rst isolated from cell lines harboring homozygous deletions on the chromosome 10q23 region by two groups Steck et al., 1997) and by a group searching for the novel tyrosine phosphatases (Li and Sun, 1997) . A series of PTEN/MMAC1 mutations were then identi®ed in sporadic tumors and cancer cell lines from various tissues including brain, endometrium, prostate, breast, thyroid, and melanoma (Risinger et al., 1997; Cairns et al., 1997; Rhei et al., 1997; Dahia et al., 1997; Guldberg et al., 1997; Teng et al., 1997) . Germline mutations of PTEN/MMAC1 were found to be associated with two inherited cancer predisposition disorders, Cowden's Syndrome (CS) Tsou et al., 1997 Tsou et al., , 1998 Nelen et al., 1997; Lynch et al., 1997) and Bannayan-Zonana Syndrome (BZS) . Functionally, PTEN/MMAC1 protein is a dual-speci®city phosphatase and has a high degree of substrate speci®city for the acidic peptide polyGlu 4 Tyr 1 Myers et al., 1997) . The loss of phosphatase activity has been associated with a subgroup of missense mutations derived from both germline and somatic origin (Myers et al., 1997) , and the catalytically inactive PTEN/ MMAC1 alleles (Furnari et al., 1997) . Overexpression of the PTEN/MMAC1 gene in 3T3 cells showed an ability to inhibited cell migration by interacting with the focal adhesion kinase (FAK) (Tamura et al., 1998) .
In Taiwan, HCC is the leading cancer in males and third leading cancer in females. The level of AFB 1 urinary metabolites was correlated positively with the incidence of developing HCC in Taiwan (Chen et al., 1996) . Most of the HCC cases were also chronic carriers of HBV. In this study, we screened a total of 96 HCCs from Taiwan which had been previously studied for HBV, AFB 1 -DNA and p53 mutations (Lunn et al., 1997) . The results demonstrated that PTEN/MMAC1 is mutated in a small subset of HCC samples containing p53 mutations, and that exon 7 missense mutation (V255A) derived from one of the HCC samples exhibited a decreased level of phosphatase activity.
Results
Sample B6-21 was obtained from a 62-year-old male with stage III HCC and positive for AFB 1 -DNA adduct and HBsAg. A missense mutation (K164E) in exon 5 of the p53 gene had been demonstrated in genomic DNA from this sample as described previously (Lunn et al., 1997) . Direct sequence analysis of this tumor's genomic DNA revealed an A?T transversion at nucleotide 431 in exon 5 of the PTEN/MMAC1 gene. This resulted in a lysine to isoleucine change in codon 144 (K144I) ( Table  1) . Genomic DNA from this individual's adjacent normal liver tissue had no detectable mutation and contained wild type sequences in both the PTEN/ MMAC1 and p53 genes.
Sample B6-2 was obtained from a 28-year-old male with stage III HCC and positive for AFB 1 -DNA adduct and HBsAg. A complete sequence analysis of genomic DNA from sample B6-2 identi®ed two sequence variants in the PTEN/MMAC1 gene. One is a T?C transition at nucleotide 764 in exon 7 resulting in a valine to alanine change in codon 255 (V255A). Another sequence variant we identi®ed was a T?A transversion at nucleotide +6 from the splice donor site of exon 3 (Table 1 ). These two sequence variants were not detected in the DNA from the same individual's adjacent normal liver tissue. Additionally, analysis of the p53 gene by PCR-SSCP showed an alteration in the genomic DNA from the same tumor sample (Lunn et al., 1997) . Sequence analysis of the PCR product containing the alteration revealed a T?G transversional change at nucleotide 401 in exon 5 which resulted in a phenylalanine to cysteine change in codon 134 of the p53 gene. This p53 mutation was not detected in DNA from adjacent normal liver tissue.
Sample B6-22 was obtained from a 47-year-old male with stage III HCC and positive for both AFB 1 -DNA adduct and HBsAg. Sequence analysis of tumor DNA revealed an A?G transition at nucleotide 288 in exon 5 which resulted in a proline to proline silent mutation in codon 96 of the PTEN/MMAC1 gene (Table 1) . Since the adjacent normal liver tissue was not available from this individual, the origin (germline or somatic) of this silent mutation is not clear. Analysis of 70 alleles from a normal population by allele-speci®c hybridization did not reveal the same sequence variant. Thus this appears to be a rare polymorphism in the PTEN/MMAC1 gene.
We then studied the functional signi®cance of these two missense mutations, K144I in exon 5 and V255A in exon 7, for their phosphatase activities on a speci®c substrate, peptide polyGlu 4 Tyr 1 . The recombinant protein containing Val255?Ala mutation showed a signi®cant decrease on the level of phosphatase activity as compard to the wild type PTEN/MMAC1 protein. Interestingly, the recombinant protein containing Lys 144?Iso showed a similar level of phosphatase activity as the wild type PTEN/MMAC1 protein (see Figure 1a and b). (b) shows that the assay is performed in triplicate and phosphatase activity of each protein is expressed as the average of free phosphatase released at 10 min
Discussion
Since the identi®cation of the PTEN/MMAC1 gene, an enormous amount of mutation screening and DNA sequencing in many human cancers has been performed. Changes in PTEN/MMAC1 structure, including point mutations, deletions, insertions and splice site mutations, have been described across all nine exons in primary tumors and cancer cell lines. The prevalence of PTEN/MMAC1 mutations varies among tumor types and ranged from 1% in thyroid tumor to 40% in glioma. In this study we detected four novel sequence variants in the PTEN/MMAC1 gene from 96 HCC samples screened. Two were missense mutations located in exon 5 and exon 7, respectively. One was a silent mutation in exon 5. The fourth sequence variant detected was a putative splice mutation in intron 3. The missense mutation K144I from sample B6-21, as was seen in most of the missense mutations found in the PTEN/MMAC1 gene, was located in or near the phosphatase signature motif (codon 122 to 134) within the phosphatase catalytic domain in exon 5. By contrast, missense mutations of the PTEN/MMAC1 gene are rare in exon 7. To date, only two missense mutations in exon 7 of the PTEN/MMAC1 gene have been reported in primary tumors, namely high grade gliomas, and none of the germline missense mutations were found in exon 7. The missense mutation (V255A) reported here is the third missense mutation found in exon 7 of the PTEN/MMAC1 gene.
Functionally, the recombinant protein containing Val255?Ala mutation showed a decreased ability to dephosphorylate peptide polyGlu 4 Tyr 1 . Interestingly, the recombinant protein contains Lys 144?Iso mutation showed no loss of phosphatase activity versus the wild type protein. Since we only performed these phosphatase assays on a single arti®cial substrate in vitro, we cannot rule out the possibility that protein containing K144I mutation has eect on the phosphatase activity on other physiological substrates. A growth inhibition study will be used to test the correlation between the level of phosphatase activity and the tumor suppressor function on these two mutants.
In this series of 96 HCC samples, 26 samples contained p53 mutations (Lunn et al., 1997) and only three samples contained PTEN/MMAC1 mutations. The ®ndings of the two PTEN/MMAC1 missense mutations occurred in the p53 mutated HCC samples suggests that both tumor suppressor genes are implicated in the etiology of HCC. All three of the HCC samples with PTEN/MMAC1 mutations were grade III tumors, a more advanced form of HCC. These data suggest that while p53 mutations are more common in HCCs, PTEN/MMAC1 mutations only occur in a small number of HCCs containing p53 mutations.
Two silent mutations have been reported in the PTEN/MMAC1 gene. A glycine to glycine change in codon 46 was identi®ed in a prostate cancer sample . A germline origin of the same silent mutation was also identi®ed in an individual with prostate cancer (Cooney et al., 1998) . We previously reported a silent mutation in exon 7 (V249V) in three individuals from one family . Here we also report a novel silent mutation (P96P) in exon 5 of the PTEN/MMAC1 gene from HCC sample B6-22.
All of three silent mutations were not detected in 70 alleles from a control normal population. While the silent mutations does not change the amino acid, there is evidence that silent mutations can cause exon skipping in the ®brillin-1 gene (Liu et al., 1997) . However, the eect of these rare silent mutations in the PTEN/MMAC1 gene is unclear.
We also detected a putative splice mutation in intron 3 (209+6T?A) from HCC sample B6-2. This sequence variant was not detected in DNAs from the adjacent normal tissues. Interestingly, a germline origin of an intronic 3 sequence variant, 209+5G?A, was reported in a CS individual (Marsh et al., 1998) and a BZS individual (unpublished data). This germline sequence variant and the HCC sequence variant in intron 3 were only one base pair apart and they were not present in 70 normal alleles. It is likely, then, that this intronic sequence variant behaves as a splice site mutation and causes exons skipping. The true functional signi®cance of this mutation is unknown.
In summary, we identi®ed four novel mutations in the PTEN/MMAC1 gene from three high grade HCC samples. The prevalence of PTEN/MMAC1 mutations in HCC is comparable to that in tumors from other tissues, such as thyroid, prostate and melanoma. We demonstrated the coexistence of a PTEN/MMAC1 mutation and a p53 mutation in two stage III HCC samples. We also demonstrated a decreased level of phosphatase activity associated with exon 7 mutation (V255A). These data provided the evidence that PTEN/MMAC1 mutations are involved in the development of HCC.
Materials and methods

Study population and design
The study population consisted of 96 primary liver tumor samples from Taiwan as described in detail (Lunn et al., 1997) .
PCR ampli®cations and direct sequencing
For mutation screening of the PTEN/MMAC1 gene, genomic DNA from each HCC sample was ampli®ed with primers anking the exons of PTEN/MMAC1 as described Tsou et al., 1997) , with a modi®cation for exons 6 and 8. Both exons 6 and 8 were not subjected to nested PCR ampli®cations. Exon 6 was sequenced with the reverse primer used in the PCR reaction and exon 8 was sequenced with primers (ATTCTTCATACCAGGACCAG and GGAGAA-AAGTATCGGTTGGC).
Cloning and sequencing of PTEN/MMAC1 cDNAs
To generate a full length PTEN/MMAC1 cDNA, we performed a reverse transcriptase PCR reaction using RNA from human dermal ®broblasts with speci®c primer pairs (F1-ACAGGCTCCCAGACATGAC and R1-TGACACAATG-TCCTATTGCCA). One tenth of the initial reaction was then subjected to a second PCR reaction with primers (F2-CAGTCTAGACACCATGACAGCCATCATCAA and R2-GCCAGGATCCATTTTATTCAA). The F2 primer incorporated a near consensus Kozak translation initiator. This product was then cloned into a pBlueScript vector (Stratagene). Mutant PTEN/MMAC1 cDNA clones were generated using a Site-Directed Mutagenesis Kit (Stratagene) with a speci®c primer¯anking the nucleotide changes.
Generation and puri®cation of wild type and mutant PTEN/MMAC1 proteins
The plasmids containing the full length of PTEN/MMAC1 cDNA, wild type and mutants, were transformed into M15 (pREP4) competent Escherichia cells and grown in medium containing ampicillin and kanamycin. The expression of the PTEN/MMAC1 proteins was induced by 2 mM isopropyl b-D-thiogalactoside (IPTG) in log phase bacteria for a period of 4 h at room temperature. Histidine-tagged PTEN/MMAC1 proteins were then puri®ed from Escherichia cell lysates using Nickel-NTA beads and the conditions recommended by the manufacturer (Qiagen). Protein concentration was determined by Bio-Rad Protein Assay, and the size and purity of the protein were veri®ed by SDS ± PAGE and Coomassie Blue stain. All proteins, wild type and mutants, were quantitated, frozen in small aliquots and maintained at 7708C.
Dephosphorylation of polyGlu 4 Tyr 1 by PTEN/MMAC1 recombinant proteins
The substrate, polyGlu 4 Tyr 1 was purchased (Sigma) and phosphorylated with AbI Protein Tyrosine Kinase (AbI, from Calbiochem). The phosphorylation reaction was performed in a buer consisting of 50 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 2 mM DTT, 0.01% Brij 35, 10 mM ATP, and 100 mCi [ 33 P]-gATP for 18 h at 308C. The phosphorylated substrate (polyGlu 4 Tyr 1 ) was separated from residual ATP by Saphadex G-25 Column (Pharmacia Biotech). For the actual phosphatase assay, 20 mg of purified recombinant PTEN/MMAC1 protein were incubated with phosphorylated polyGlu 4 Tyr 1 in a phosphatase buer (50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 5 mM DTT, 0.01% Brij 35, 1 mg/ml BSA) at 308C. The reaction were then terminated by 200 ml of cold 20% TCA at 10, 20 and 30 min. After centrifugation, the released inorganic phosphate in the supernatant at each time point was quantitated by liquid scintillation counting.
